ライフサイエンスコーパス: tumor-specific antigen

1 rough improved immune surveillance against a tumor-specific antigen.

2 Id) protein, secreted by myeloma cells, is a tumor-specific antigen.

3 membrane protein could be transformed into a tumor-specific antigen.

4 containing a conventional plasmid carrying a tumor-specific antigen.

5 nes (BCR-ABL) oncogen product is a potential tumor-specific antigen.

6 ts (idiotype [Id]) that can be regarded as a tumor-specific antigen.

7 erminant (idiotype [Id]) that may serve as a tumor-specific antigen.

8 zes the human and murine equivalents of this tumor-specific antigen.

9 on that does not depend on identification of tumor-specific antigens.

10 the melanoma antigen gene (MAGE-I) family of tumor-specific antigens.

11 8+ cytotoxic T cell responses against murine tumor-specific antigens.

12 nt on transplantable tumors, not against the tumor-specific antigens.

13 The MAGE proteins are best known as curious tumor-specific antigens.

14 uction of immunity to weak antigens, such as tumor-specific antigens.

15 sequences represent potentially immunogenic tumor-specific antigens.

16 sponses against viral, tumor-associated, and tumor-specific antigens.

17 lementation of CAR therapy is the paucity of tumor-specific antigens.

18 protein is a surprisingly broad, yet highly tumor-specific, antigen.

19 ow that host T cells properly primed against tumor-specific antigens after conventional treatment, wh

20 The high affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies

21 pressed by malignant B cells, idiotype, is a tumor-specific antigen and an attractive target for acti

22 B-cell malignancy (Id) can serve as a unique tumor-specific antigen and as a model for cancer vaccine

23 t has been hampered by the lack of universal tumor-specific antigens and a limited understanding of t

24 ncogenic proteins, such as E7, are promising tumor-specific antigens and are obligatory for tumor gro

25 Despite the existence of tumor-specific antigens and demonstrated presence of tum

26 ese findings highlight an important class of tumor-specific antigens and have implications for target

27 olid tumors is hampered by the lack of truly tumor-specific antigens and poor control over T cell act

28 show that MYCN-derived peptides can serve as tumor-specific antigens and suggest a rational approach

29 The combination of CRCL as a source of tumor-specific antigens and Th-1 lymphocytes as an adjuv

30 obstacles facing CAR T cells are scarcity of tumor-specific antigens and the hostile and complex tumo

31 The limited number of targetable tumor-specific antigens and the immunosuppressive nature

32 ulatory processes, which cause expression of tumor-specific antigens and tumor-associated antigens (T

33 mplex due to cellular heterogeneity, lack of tumor-specific antigens, and an immunosuppressive tumor

34 ng mRNAs encoding tumor-associated antigens, tumor-specific antigens, and immune stimulatory factors,

35 h frequencies of TCRs predicted to recognize tumor-specific antigens, and these tumor-specific TCRs u

36 The ADC based approach is developed with tumor specific antigen, antibody carrying cytotoxic agen

37 CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients

38 Many tumor-specific antigens are mutant proteins that are pre

39 specific antibodies (TCBs) targeting CD3 and tumor-specific antigens are very promising therapeutic m

40 By harnessing tumor-specific antigens as allergens, IgE-MCs accumulate

41 al growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR pr

42 te-associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield

43 MJ23 T(regs) were not reactive to a tumor-specific antigen but instead recognized a prostate

44 that single-chain antibody fragments against tumor-specific antigens can be inserted at the N terminu

45 apy in which cytotoxic T cells (CTLs) target tumor-specific antigens complexed to MHC-I molecules has

46 Advances in the identification of tumor-specific antigens coupled with a greater understan

47 The tumor-specific antigen, cytokines and cell debris libera

48 read occurrence and strong immunogenicity of tumor-specific antigens derived from shared frameshift m

49 e phosphatase placental-like 2 (ALPPL2) as a tumor-specific antigen expressed in a spectrum of solid

50 mor antigen (Tag) represents a virus-encoded tumor-specific antigen expressed in many types of human

51 ularly in indications with high, stable, and tumor-specific antigen expression.

52 of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a therapeutic vaccine.

53 his review, we discuss the identification of tumor-specific antigens for cancer therapy, the benefits

54 tumor cells produced hs2dAb directed against tumor-specific antigens further highlighting the potenti

55 Because tumor-specific antigens have been identified in multiple

56 However, few truly tumor-specific antigens have been identified, and health

57 Subunit vaccines inducing antibodies against tumor-specific antigens have yet to be clinically succes

58 rum-centric database searching, prioritizing tumor-specific antigens, identifying missing proteins, a

59 Enhanced cytosolic bioavailability of tumor-specific antigens improves access to human leukocy

60 Leukemia cells may express tumor specific antigens in association with Class I and

61 ), also known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

62 Such sequences may thus comprise absolutely tumor-specific antigens in a peptide-based vaccine.

63 herapy using monoclonal antibodies against a tumor-specific antigen is now an established mode of the

64 Immunotargeting of tumor-specific antigens is a powerful therapeutic strate

65 In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activat

66 that active immunization with genes encoding tumor-specific antigens may be an efficacious strategy f

67 een a hypothetical concern that mutations in tumor-specific antigens may lead to tumor escape.

68 arget toxicity, but the chimera results in a tumor-specific antigen (neoantigen) that may be targeted

69 Targeting tumor-specific antigens obviates the issue of central im

70 model considers the vaccine concentration of tumor-specific antigen peptides and adjuvant, the patien

71 man cancers could be an unexplored source of tumor-specific antigens, potentially mediating anti-tumo

72 sma cell differentiation results in enhanced tumor-specific antigen presentation by B cells and there

73 otherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC).

74 In an effort to identify tumor-specific antigens recognized by CD4(+) T cells, an

75 of the quaternary structure of the secreted tumor-specific antigen reduces its immunogenicity.

76 Unfortunately, tumor-specific antigens remain challenging to identify a

77 mal tissues, and there is a paucity of truly tumor-specific antigens shared across tumor types.

78 unization of allogeneic BMT donors against a tumor-specific antigen significantly enhances GVT activi

79 es of the innate immune response against the tumor-specific antigen simian virus 40 (SV40) large tumo

80 against malignant cell types that express a tumor-specific antigen such as SV40 Tag.

81 strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic protei

82 CD) of cell-surface receptors could serve as tumor-specific antigens that are accessible to antibody

83 In the future, the molecular definition of tumor-specific antigens that are recognized by activated

84 the utility of this approach for identifying tumor-specific antigens that are the targets of a CTL re

85 et antigen expression, and lack of bona fide tumor-specific antigens that can be targeted without cro

86 uous' repair mechanisms and the induction of tumor-specific antigens that can be targeted.

87 ients with cutaneous T-cell lymphoma express tumor-specific antigens that can serve as the targets of

88 we have studied two CD4(+) T cell-recognized tumor-specific antigens that were retained during evolut

89 in stimulating type 1 responses against our tumor-specific antigen, the male antigen, HY.

90 targeting the host's immune response against tumor-specific antigens, thereby eradicating cancer cell

91 on to the type as well as level of expressed tumor-specific antigens, thereby presenting methods for

92 (LNPs) 100-200 nm in size-enable delivery of tumor-specific antigens to activate immune responses.

93 dendritic cells and prevents presentation of tumor-specific antigens to other immune cells.

94 solid tumors that include the lack of highly tumor-specific antigens to target, opening up the possib

95 bacterium, is a potent vector for targeting tumor-specific antigens to the immune system.

96 ved Ig, the idiotype of which can serve as a tumor-specific antigen, to test the principle of transfe

97 Tumor-specific antigen (TSA) identification in human can

98 Re-activation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critic

99 dysfunction." Additionally, the sparsity of tumor-specific antigens (TSA) and expression of CAR-dire

100 on of low-abundance MHC I peptides including tumor-specific antigens (TSAs) and minor histocompatibil

101 alloantigens, although both alloantigens and tumor-specific antigens (TSAs) initiate GVT responses.

102 We identified 25 tumor-specific antigens (TSAs) mainly deriving from aber

103 to these limitations include the scarcity of tumor-specific antigens (TSAs), insufficient CAR-T cell

104 essed on the surface of B-cell lymphomas are tumor-specific antigens (TSAs), which can be targeted by

105 remains limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppressi

106 The nanodrug binds the tumor-specific antigen uMUC-1, which is found in >90% of

107 ly dependent on the efficient recognition of tumor-specific antigens via T cell receptors.

108 Lymphomas express a tumor-specific antigen which can be targeted by cancer v

109 immunization of BMT donors against a defined tumor-specific antigen with a vaccine not containing rec